Log in to save to my catalogue

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leuk...

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leuk...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1566841019

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

About this item

Full title

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2014-09, Vol.15 (10), p.1090-1099

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL. Methods In this single-a...

Alternative Titles

Full title

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1566841019

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1566841019

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(14)70335-3

How to access this item